PMV Pharmaceuticals Inc (PMVP)
1.66
+0.02
(+1.22%)
USD |
NASDAQ |
Nov 05, 16:00
1.66
0.00 (0.00%)
After-Hours: 16:10
PMV Pharmaceuticals Enterprise Value: -128.43M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -128.43M |
| November 01, 2024 | -128.94M |
| October 31, 2024 | -128.94M |
| October 30, 2024 | -131.00M |
| October 29, 2024 | -127.91M |
| October 28, 2024 | -127.40M |
| October 25, 2024 | -127.40M |
| October 24, 2024 | -127.40M |
| October 23, 2024 | -130.49M |
| October 22, 2024 | -124.82M |
| October 21, 2024 | -131.00M |
| October 18, 2024 | -131.52M |
| October 17, 2024 | -130.49M |
| October 16, 2024 | -130.49M |
| October 15, 2024 | -136.15M |
| October 14, 2024 | -135.64M |
| October 11, 2024 | -136.15M |
| October 10, 2024 | -135.12M |
| October 09, 2024 | -136.15M |
| October 08, 2024 | -136.41M |
| October 07, 2024 | -135.64M |
| October 04, 2024 | -134.09M |
| October 03, 2024 | -136.67M |
| October 02, 2024 | -136.15M |
| October 01, 2024 | -135.64M |
| Date | Value |
|---|---|
| September 30, 2024 | -136.15M |
| September 27, 2024 | -135.64M |
| September 26, 2024 | -136.41M |
| September 25, 2024 | -136.15M |
| September 24, 2024 | -136.15M |
| September 23, 2024 | -136.15M |
| September 20, 2024 | -135.64M |
| September 19, 2024 | -134.61M |
| September 18, 2024 | -135.12M |
| September 17, 2024 | -135.64M |
| September 16, 2024 | -135.64M |
| September 13, 2024 | -135.12M |
| September 12, 2024 | -136.15M |
| September 11, 2024 | -135.12M |
| September 10, 2024 | -136.15M |
| September 09, 2024 | -134.61M |
| September 06, 2024 | -135.64M |
| September 05, 2024 | -134.09M |
| September 04, 2024 | -135.12M |
| September 03, 2024 | -131.52M |
| August 30, 2024 | -132.03M |
| August 29, 2024 | -130.49M |
| August 28, 2024 | -131.00M |
| August 27, 2024 | -131.52M |
| August 26, 2024 | -130.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.99M
Minimum
Oct 25 2023
2.393B
Maximum
Dec 31 2020
440.26M
Average
260.00M
Median
Sep 21 2022
Enterprise Value Benchmarks
| Marker Therapeutics Inc | 23.61M |
| CEL-SCI Corp | 50.50M |
| AIM ImmunoTech Inc | 8.843M |
| IGC Pharma Inc | 26.81M |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.213M |
| Total Expenses (Quarterly) | 20.17M |
| EPS Diluted (Quarterly) | -0.02 |
| Earnings Yield | -58.43% |